446 related articles for article (PubMed ID: 25885880)
1. Portopulmonary Hypertension in Liver Disease Presenting in Childhood.
Ecochard-Dugelay E; Lambert V; Schleich JM; Duché M; Jacquemin E; Bernard O
J Pediatr Gastroenterol Nutr; 2015 Sep; 61(3):346-54. PubMed ID: 25885880
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre.
Lambert V; Ladarre D; Fortas F; Durand P; Hervé P; Gonzales E; Guérin F; Savale L; McLin VA; Ackermann O; Franchi-Abella S;
Arch Cardiovasc Dis; 2021 Mar; 114(3):221-231. PubMed ID: 33281106
[TBL] [Abstract][Full Text] [Related]
3. Portopulmonary hypertension: Results from a 10-year screening algorithm.
Krowka MJ; Swanson KL; Frantz RP; McGoon MD; Wiesner RH
Hepatology; 2006 Dec; 44(6):1502-10. PubMed ID: 17133488
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in pulmonary hepatic vascular diseases.
Horvatits T; Fuhrmann V
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):31-42. PubMed ID: 24308785
[TBL] [Abstract][Full Text] [Related]
5. Portopulmonary hypertension.
Mukhtar NA; Fix OK
J Clin Gastroenterol; 2011 Sep; 45(8):703-10. PubMed ID: 21325952
[TBL] [Abstract][Full Text] [Related]
6. [Pulmonary complications of hepatic cirrhosis: portopulmonary hypertension and hepatopulmonary syndrome. The paradox of pulmonary vasoconstriction and vasodilation].
Chávez-Tapia NC; Uribe M; López E
Gac Med Mex; 2007; 143(4):333-9. PubMed ID: 17969842
[TBL] [Abstract][Full Text] [Related]
7. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
Joye R; Lador F; Aggoun Y; Farhat N; Wacker J; Wildhaber BE; Vallée JP; Hachulla AL; McLin VA; Beghetti M
J Hepatol; 2021 Mar; 74(3):742-747. PubMed ID: 33276028
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.
Talwalkar JA; Swanson KL; Krowka MJ; Andrews JC; Kamath PS
Gastroenterology; 2011 Nov; 141(5):1673-9. PubMed ID: 21723219
[TBL] [Abstract][Full Text] [Related]
9. Portopulmonary Hypertension and Liver Transplant: Recent Review of the Literature.
Cosarderelioglu C; Cosar AM; Gurakar M; Pustavoitau A; Russell SD; Dagher NN; Gurakar A
Exp Clin Transplant; 2016 Apr; 14(2):113-20. PubMed ID: 27015528
[TBL] [Abstract][Full Text] [Related]
10. Volume-mediated pulmonary responses in liver transplant candidates.
Kuo PC; Schroeder RA; Vagelos RH; Valantine H; Garcia G; Alfrey EJ; Haddow G; Dafoe DC
Clin Transplant; 1996 Dec; 10(6 Pt 1):521-7. PubMed ID: 8996773
[TBL] [Abstract][Full Text] [Related]
11. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era.
Mandell MS
Liver Transpl; 2004 Oct; 10(10 Suppl 2):S54-8. PubMed ID: 15382220
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension in patients with congenital portosystemic venous shunt: a previously unrecognized association.
Ohno T; Muneuchi J; Ihara K; Yuge T; Kanaya Y; Yamaki S; Hara T
Pediatrics; 2008 Apr; 121(4):e892-9. PubMed ID: 18362102
[TBL] [Abstract][Full Text] [Related]
13. Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation.
Pham DM; Subramanian R; Parekh S
J Clin Gastroenterol; 2010 Aug; 44(7):e136-40. PubMed ID: 20463591
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.
Krowka MJ; Wiesner RH; Heimbach JK
J Hepatol; 2013 Aug; 59(2):367-74. PubMed ID: 23557870
[TBL] [Abstract][Full Text] [Related]
15. Liver in cardiopulmonary disease.
Polavarapu N; Tripathi D
Best Pract Res Clin Gastroenterol; 2013 Aug; 27(4):497-512. PubMed ID: 24090938
[TBL] [Abstract][Full Text] [Related]
16. Portopulmonary hypertension and hepatopulmonary syndrome.
Hoeper MM; Krowka MJ; Strassburg CP
Lancet; 2004 May; 363(9419):1461-8. PubMed ID: 15121411
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of clinical features and targeted drug therapy of portopulmonary hypertension].
Yang SQ; Yang YH; Kuang TG; Liu L; Gong JN; Ding Y; He JG
Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2806-2810. PubMed ID: 31550806
[No Abstract] [Full Text] [Related]
18. Pulmonary vascular complications in portal hypertension and liver disease: a concise review.
Porres-Aguilar M; Gallegos-Orozco JF; Garcia H; Aguirre J; Macias-Rodriguez RU; Torre-Delgadillo A
Rev Gastroenterol Mex; 2013; 78(1):35-44. PubMed ID: 23369639
[TBL] [Abstract][Full Text] [Related]
19. A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation.
Saragai Y; Takaki A; Umeda Y; Matsusaki T; Yasunaka T; Oyama A; Kaku R; Nakamura K; Yoshida R; Nobuoka D; Kuise T; Takagi K; Adachi T; Wada N; Takeuchi Y; Koike K; Ikeda F; Onishi H; Shiraha H; Nakamura S; Morimatsu H; Ito H; Fujiwara T; Yagi T; Okada H
BMC Gastroenterol; 2018 May; 18(1):62. PubMed ID: 29764373
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
